Phase II Study of Novantrone(R) (Mitoxantrone) and Etoposide in Patients With HIV Associated Large Cell and Immunoblastic Lymphomas

Phase 2

Completed

• Conditions: Lymphoma, Non-Hodgkin; HIV Infections

• Registration Number: NCT00002003
• Lead Sponsor: Lederle Laboratories

Brief Summary

To determine the efficacy and toxicity of the combination of mitoxantrone hydrochloride ( Novantrone ) and etoposide in the treatment of patients with HIV associated lymphomas.

Detailed Description

Not available

Study Timeline

• Status Verified: 1992-03
• Study First Submitted: 1999-11-02
• Study First Submitted QC: 2001-08-30
• Study First Posted: 2001-08-31
• Last Update Submitted: 2005-06-23
• Last Update Posted: 2005-06-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: Not specified

Trial Locations

Locations (3)

UMDNJ - New Jersy Med School; 🇺🇸 Newark, New Jersey, United States

New York Univ Med Ctr; 🇺🇸 New York, New York, United States

Saint Luke's - Roosevelt Hosp Ctr; 🇺🇸 New York, New York, United States